Hu Kaijun (#1138)
- $ 4 B
- Pharmaceuticals
- China
- M
- 64 Years
Rest in Peace Ask Jeeves, every search comes to an end
County commissioners call on lawmakers to up funding for 911 dispatch systems
Spirit Airlines Is Going Out Of Business; Effective IMMEDIATELY
Pokémon Scalpers Selling Limited-Edition Pop-Tarts For Ridiculous Prices
Bennett says Netanyahu gov't 'boycotting' West Bank settlements amid Carrefour subsidy deal
Golf gear on sale now: Up to 65% off adidas, 45% off Puma, 15% off Mizuno, more
Families across the US can't find childcare — this map shows where it's worst
Median sales surge 61% in a Queens neighborhood that’s now the fifth priciest in NYC
Greg Brockman says his stake in OpenAI is worth nearly $30 billion
TeraWulf Announces Participation in Upcoming Investor and Industry Conferences
About Me
Hu Kaijun is chairman and CEO of China Grand Enterprises, an investment company with interests in healthcare, real estate, agriculture and financial services. China Grand is the parent of three publicly-traded companies: Grand Pharmaceutical, Huadong Medicine (a wholesaler) and Grand Industrial Holding (a trading business). Grand Pharmaceutical agreed to buy 87.5% of U.S.-based vascular drug maker BlackSwan Vascular for $37.5 million in 2023. Hu also wholly owns Beijing Yuanda Huachuang Investment, where he also serves as chairman and CEO. Hu's wealth is derived primarily from Grand China's stakes in Huadong Medicine and Grand Pharmaceutical.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Hu Kaijun’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Hu Kaijun’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $3.8B
(May 4, 2026)
© Iconic Billionaires